Table 2.
Cytology, % | <1 | 1-49 | ≥50 |
---|---|---|---|
Lund cohort | Biopsy | ||
<1 | 11 | 2 | 1 |
1–49 | 0 | 11 | 4 |
≥50 | 0 | 0 | 18 |
| |||
Halmstad cohort | Biopsy | ||
<1 | 40 | 12 | 2 |
1–49 | 4 | 10 | 7 |
≥50 | 0 | 6 | 16 |
PD-L1, programmed death-ligand 1; NSCLC, non-small cell lung cancer.
Cytology, % | <1 | 1-49 | ≥50 |
---|---|---|---|
Lund cohort | Biopsy | ||
<1 | 11 | 2 | 1 |
1–49 | 0 | 11 | 4 |
≥50 | 0 | 0 | 18 |
| |||
Halmstad cohort | Biopsy | ||
<1 | 40 | 12 | 2 |
1–49 | 4 | 10 | 7 |
≥50 | 0 | 6 | 16 |
PD-L1, programmed death-ligand 1; NSCLC, non-small cell lung cancer.